Cell Genesys terminates Ph III trial of prostate cancer immunotherapy and slashes staff
This article was originally published in Scrip
Cell Genesyswill place on hold the further development of GVAX immunotherapy for prostate cancer, its lead developmental candidate, pending a review of the programme with its collaboratorTakeda, and dramatically reduce its staff after the failure of a second Phase III pivotal trial. It said it would consider appropriate strategic alternatives for the company, which it plans to do in an "expeditious manner".
You may also be interested in...
A well-orchestrated build-up to the annual J.P. Morgan Healthcare Conference and subsequent rush of fundraisings was helped by the acquisition of Ariad by Takeda early last week. But the good times were derailed by a drug-pricing diversion, unleashed by the US president-elect.
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.